Loading stock data…
Phathom Pharmaceuticals (PHAT)
$10.91+0.04 (+0.37%)
Market OpenUpdated 3:12 PM EDT
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Phathom Pharmaceuticals, Inc. in the Healthcare sector is trading at $10.91 with a market capitalization of $843M. Wall Street consensus targets $23.70 (10 analysts), implying a +117.2% move over the next 12 months. The stock is currently 40% below its 52-week high of $18.31, remaining 14.2% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +117.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $58.30M↑ | $57.58M↑ | $49.50M↑ | $39.50M↑ | $28.52M |
| Gross Profit | $46.30M↓ | $49.94M↑ | $43.31M↑ | $34.47M↑ | $24.80M |
| Operating Income | -$15.48M↓ | -$5.93M↑ | -$15.27M↑ | -$59.92M↑ | -$78.86M |
| Net Income | -$30.37M↓ | -$21.15M↑ | -$29.97M↑ | -$75.81M↑ | -$94.32M |
Peer Comparison
JNJUNHPFE
Fundamentals
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$843.42M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
46.68%
Volume
Today's trading volume
360,350
Recent News
Phathom Pharmaceuticals (PHAT) Is Up 11.0% After Narrowing Q1 Loss And Reaffirming 2026 Profitability Timeline
Phathom Pharmaceuticals, Inc. reported first-quarter 2026 results showing a net loss of US$30.37 million, down from US$94.32 million a year earlier, with basic loss per share from continuing operations narrowing to US$0.37 from US$1.31. The company also maintained its 2026 guidance, including expected net revenues of US$320 million to US$345 million and a target of reaching operating profitability, excluding stock-based compensation, by the third quarter and for the full year, while changing...
How The Phathom Pharmaceuticals (PHAT) Narrative Is Shifting Around Profitability And Exclusivity Risks
Price targets on Phathom Pharmaceuticals have been refreshed in recent reports, with some moving to US$25 and others to US$13 as analysts rework their models. These updated targets reflect a mix of optimism around the company’s stated goal of reaching profitability in early Q3 2026, along with caution around long term exclusivity, regulatory factors, and commercialization efforts. As you read on, you will see how to interpret these shifting targets and track the evolving Street narrative...
Phathom Pharmaceuticals Q1 Earnings Call Highlights
Phathom Pharmaceuticals (NASDAQ:PHAT) reported first-quarter 2026 net revenue of $58.3 million, more than doubling the $28.5 million recorded in the same period a year ago, as the company emphasized continued progress in deepening adoption of its acid-suppression medicine VOQUEZNA among gastroentero
Phathom Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Moby summary of Phathom Pharmaceuticals, Inc.'s Q1 2026 earnings call
Phathom (PHAT) Q1 2026 Earnings Transcript
Hello, everyone, and thank you for joining us this morning to discuss Phathom's first quarter 2026 results. This morning's presentation will include remarks from Steve Basta, our President and CEO; and Sanjeev Narula, our Chief Financial and Business Officer. Before we begin, let me remind you that we will be making a number of forward-looking statements throughout today's presentation.